Podcasts about biomarkers

If you found out earlier on in your youth that you actually have a genetic propensity toward addiction, would you have made decisions a lot differently? Addiction is a bio-psycho-social model, but we don't really look at the bio part of it. Sometimes, we have to look at the physiology of things to understand addiction better. And there has to be a paradigm shift in thinking about how we operate and exist in this world.  On today's episode, Duane speaks with Dr. Evelyn Higgins about genes and biomarkers, how they influence our behavior, how they play out in addiction, and why knowing about this part of ourselves is an important step in addiction treatment and recovery.  Dr. Evelyn Higgins is the founder and CEO of Wired For Addiction and a recognized international expert in the epidemiology of addiction. With 34 years in clinical practice, Dr. Higgins has spent over 16 years dedicated to research and development in the science of addiction recovery, and she finds herself at the nexus of epigenetics, neuroscience, and addiction.  In this episode, you will hear: What it means to look at errors in genetic coding Epigenetics and aberrant behaviors Why addiction is not a moral flaw, but a disease The first step is getting objective information. The common genetic markers of addiction How seeing addiction from a biological perspective impacts the families Subscribe and Review Have you subscribed to our podcast? We'd love for you to subscribe if you haven't yet.  We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Supporting Resources: Wired For Addiction Dr. Higgins' TEDTalk: https://www.youtube.com/watch?v=8XNk8tNsaco  NovusMindfulLife.com Episode Credits If you like this podcast and are thinking of creating your own, consider talking to my producer, Emerald City Productions. They helped me grow and produce the podcast you are listening to right now. Find out more at https://emeraldcitypro.com Let them know we sent you. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to another episode of the Biohacking Beauty podcast brought to you by Young Goose Skincare! In this episode, host Amitay Eshel, the CEO of Young Goose, is joined by Dr. Molly Maloof.Dr. Maloof is the founder and CEO of Adamo Bioscience, a company pioneering the science of love. She provides personalized medicine to world-class entrepreneurs, investors, and technology executives in Silicon Valley. Since 2012, she has worked as an advisor or consultant to over 50 companies in the digital health, consumer health, and biotechnology industries. She teaches a course on healthspan at the Medical School at Stanford University.Key Takeaways:Women have different biological processes in their bodies from men, such as the production of estrogen and other types of hormones as well as a menstrual cycle that is likely to impact their body's ability to reap the benefits of certain biohacking protocols. They must consider this and adapt accordingly.Women go through four different stages in their menstrual cycle where their bodies simply can't handle the same consistent amount of stress, whether it is physical or emotional, at every stage of their cycle. As result, women may not be performing at their absolute best nor reaping the most benefits from their efforts to be in good health if they disregard their menstrual cycle. This is the complete opposite of men, who can take on stressors at any time and be able to push through. Skin autofluorescence is a non-invasive biomarker often used in the medical field as a diagnostic tool for different health concerns, such as diabetes, heart disease, and cognitive impairment among other things. But what most people don't know is that when your overall health is in top shape, skin autofluorescence is responsible for that glowing skin you have! Glowing of any kind whether it be your skin or your hair being glossy is an important biomarker for good health.What we discuss:04:30: About Dr. Maloof's book05:50: What themes does Dr. Maloof cover in her new book?12:15: How should biohacking be approached by women?19:25: The skew about women's representation in medical research21:02: Which biomarkers should women track?25:22: How can you improve gut health?28:52: What is metabolic flexibility?34:00: Do women have a different relationship with stress than men?37:59: How do you recover from stress?40:38: What are the latest emerging biohacking strategies?42:36: What does Dr. Maloof think of Methylene Blue?45:12: What other supplements does Dr. Maloof take?49:50: What does Dr. Maloof do to improve brain function?51:55: What is Dr. Maloof's experience with psychedelics?58:02: Are we working hard enough for dopamine and serotonin?1:00:43: Is sugar a drug?1:06:22: What is the next thing Dr. Maloof plans to work on?01:09:55: More about Dr. MaloofTo learn more about Dr. Maloof:Book: The Spark Factor: The Secret to Supercharging Energy, Becoming Resilient, and Feeling Better Than EverWebsite: https://drmolly.co/ Instagram: @drmolly.coTo learn more about Young Goose:Website: https://www.younggoose.com/Instagram:

Dr. Campbell and Dr. Hohn are joined by Noelle Tarr, a Nutritional Therapy Practitioner and host of the top-ranked women's health and fitness podcast, Well-Fed Women. Together, we discuss the challenges of navigating today's beauty standards and body image. We discuss the impact of social media on body image and how to set healthy boundaries with it. Noelle also explains biomarkers of health beyond the scale, the benefits of exercise regardless of weight loss, and the importance of cultivating a healthy relationship with food. Tune in to learn how you can create a positive relationship with food and fitness with Noelle's tips and advice.    TOPICS: Meet Noelle Tarr (00:40) The pressures of beauty and body image (01:55) Biomarkers of health without the scale (11:00) The impact of social media (19:50) Improving your body image (23:17) Exercise benefits, regardless of weight loss (29:15) Cultivating a healthy relationship with food (39:15)   MORE FROM THE HEALTH BABES:   Did you know? You have a chance to win 1 of 2 prizes, with a giveaway in every episode! Leave a review to win, and don't forget to subscribe for future episodes!   Follow Noelle Tarr on Instagram @coconutsandkettlebells Check out her website at coconutsandkettlebells.com Listen to the Well-Fed Women Podcast Purchase a copy of Coconuts and Kettlebells   Find more from Dr. Becky Campbell and Dr. Krystal Hohn at DrBeckyCampbell.com Consult with us one on one HERE   Follow Dr. Becky and Dr. Krystal on Instagram @drbeckycampbell and @drkrystalhohn, follow the Health Babes Podcast @healthbabespodcast Find us on Facebook, on Pinterest, and on YouTube   Get resources on how best to support your thyroid HERE Wondering if you have histamine intolerance? Take THIS QUIZ and receive a free histamine guide Get answers to your health questions HERE

Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGastroesophageal22).

It's episode 1 of season 6! We're kicking off the new year with a discussion about polypharmacy in the forensic setting and biomarkers for FND in children. The references for this episode are: Farrell, C., & Brink, J. (2020). The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample. Frontiers in psychiatry, 11, 263. https://doi.org/10.3389/fpsyt.2020.00263Chung, J., Mukerji, S., & Kozlowska, K. (2023). Cortisol and α-amylase awakening response in children and adolescents with functional neurological (conversion) disorder. The Australian and New Zealand journal of psychiatry, 57(1), 115–129. https://doi.org/10.1177/00048674221082520The Psych Review was brought to you by Call to Mind, a telepsychiatry service that you can learn more about at www.calltomind.com.au. The original music in our podcast was provided by the very talented John Badgery, and our logo was designed by the creative genius of Naz.

Understanding how living cells work is difficult due to the number of varied and complex processes occurring in them. This complexity can be elucidated by breaking these processes down and focusing on a particular mechanism. One approach is to use mathematical equations – the basis of computational modelling. Dr Susan Mertins, the founder and CEO of Biosystem Strategies LLC, in the USA, is exploring how ordinary differential equations and machine learning can be applied to cancer data for biomarker discovery and drug development, leading to improvements in personalised medicine.Read more in Research OutreachRead some of their latest work here: https://doi.org/10.3389/fonc.2021.805592

A new research paper was published on the cover of Aging (listed as "Aging (Albany NY)" by Medline/PubMed and "Aging-US" by Web of Science) Volume 14, Issue 24, entitled, “Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers.” Capturing the genetic architecture of Alzheimer's disease (AD) is challenging because of the complex interplay of genetic and non-genetic factors in its etiology. It has been suggested that AD biomarkers may improve the characterization of AD pathology and its genetic architecture. Most studies have focused on connections of individual genetic variants with AD biomarkers, whereas the role of combinations of genetic variants is substantially underexplored. In this new study for the Alzheimer's Disease Neuroimaging Initiative, researchers, from Alexander M. Kulminski, Ethan Jain-Washburn, Elena Loiko, Yury Loika, Fan Feng, and Irina Culminskaya from Duke University and University of California examined the associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising the ε4-encoding rs429358, TOMM40 rs2075650, and APOC1 rs12721046 polymorphisms with cerebrospinal fluid (CSF) and plasma amyloid β (Aβ40 and Aβ42) and tau biomarkers. “Here, we examine the associations of the APOE ε2 and ε4 alleles and the AD-risk-differentiating compound genotypes comprising rs429358, rs2075650, and rs12721046 SNPs with Aβ40, Aβ42, and tau AD biomarkers measured in CSF and plasma using data from three studies: the AD Neuroimaging Initiative (ADNI), the Atherosclerosis Risk in Communities (ARIC) study, and the Framingham Heart Study (FHS).” Findings from this study support associations of the ε4 alleles with both plasma and CSF Aβ42 and CSF tau, and the ε2 alleles with baseline, but not longitudinal, CSF Aβ42 measurements. The researchers found that the ε4-bearing polygenic profiles conferring higher and lower AD risks are differentially associated with tau but not Aβ42. Modulation of the effect of the ε4 alleles by TOMM40 and APOC1 variants indicates the potential genetic mechanism of differential roles of Aβ and tau in AD pathogenesis. “Our primary finding is that the ε4-bearing polygenic profiles conferring higher and lower AD risks are differently associated with tau but not Aβ42. The other main results of our work are characterizations of the associations of the APOE ε2 and ε4 alleles with Aβ40, Aβ42, and tau biomarkers in ADNI-1, ADNI-2/GO, ARIC, and three FHS cohorts.” DOI: https://doi.org/10.18632/aging.204384 Corresponding Author: Alexander M. Kulminski - kulminsk@duke.edu Keywords: aging, apolipoprotein E polymorphism, Alzheimer's disease, haplotypes, Alzheimer's disease biomarkers Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204384 About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMetastaticBladderCancer22).

Dr. Howard Fillit, the Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, focuses the nonprofit on supporting scientists around the globe who are investigating novel drugs to prevent, treat and cure Alzheimer's disease. He explains to hosts Mark Masselli and Margaret Flinter how those investments are paying dividends in terms of diagnostic tools and treatments and why the upcoming holidays are a perfect time to assess if a loved one is showing signs of dementia.

Drs. Safa Rahmani, Kat Talcott, and Sarwar Zahid join to discuss the January 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include the coding for geographic atrophy injections, private equity perspectives, biomarkers for diabetic retinopathy, and early worsening of diabetic retinopathy with anti-diabetic medications.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Talcott is a consultant for Genentech, Regenxbio, and Zeiss. Dr. Rahmani has received research funding from Regeneron. Dr. Zahid has no relevant disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Commentary by Dr. Valentin Fuster

In this episode, we discuss aging and brain health with Dr. Rhoda Au.  Specifically, we cover the Framingham Heart Study and cardiovascular risk factors, the Boston Process Approach, Alzheimer's disease, and digital biomarkers. Show notes are available at www.NavNeuro.com/110 _________________ If you'd like to support the show, here are a few easy ways: 1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarkers-in-alzheimers-disease/14651/ TBD

Host: Marc E. Agronin, MD Guest: Richard S. Isaacson, MD TBD

In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer?   Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

In this episode, Austin J (hallucinodream) wraps up the year with announcemetns for whatr is to come in 2023! Ranging from new video content, blogs, a change in the podcast, and more! We wish everyone happy holiday's and a great end of the year! *Episode disclaimer: Please note that nobody in this episode is a doctor, a registered dietician or any medical professional. The information in this episode is purely research based or anecdotal based. This information is not to be used to diagnose, treat, or cure any medical condition. The episode is for educational purposes. This episode is hosted by Austin J (@hallucinodream)! If you have any questions on anything you heard in this episode, feel free to ask by sending us a message on any of our social media platforms and we will be happy to answer them in follow up episodes! Also, be sure to put some tips to use, and share your stories with us on social media! Ready to get the same blood panel that Austin J (hallucinodream) gets? Check out Inside Tracker's plan and pick the one that suits your needs! Use the code below for a discount that can be used across the whole online store! -Inside Tracker: https://www.insidetracker.com/ -25% off full store with code: AUSTINPRO25 // Enjoying the Podcast? Help support us by becoming a Patreon today! // https://www.patreon.com/1PUNCH // Each tier comes with their own benefits! // Be sure to check them out and choose the best suited for you! // And as always, thank you in advance for the love and support! ----- Podcast Posting Schedule: -1st and 3rd Thursday of every month: Regular Episode -2nd and 4th Thursday of every month: Follow up and Q&A to previous week's podcast. -5th Thursday of every month: Fun Episode with more Q&A from current or past episodes! Check us out on our website and social media: -Website: https://www.1PUNCH.net -Instagram: https://www.instagram.com/1PUNCHNation -TikTok: https://www.tiktok.com/@1PUNCHNation -Twitter: https://www.twitter.com/1PUNCH -Twitch: https://www.twitch.tv/1PUNCH -YouTube: https://www.youtube.com/1PUNCH Check out those who took part in this podcast: Host: Austin J / hallucinodream -Instagram: https://www.instagram.com/hallucinodream -TikTok: https://www.tiktok.com/@hallucinodream -Twitter: https://www.twitter.com/hallucinodream -Twitch: https://www.twitch.tv/hallucinodream -YouTube: https://www.youtube.com/hallucinodream Thank you for the support, and don't forget to hit that subscribe button! #1PUNCH #Health #Wellness #Gaming #Podcast #Nutrition #Carbohydrates #Carbs

In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer?   Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarianPARP22).

What biomarkers does your doctor measure? During my conversation with experts practising in diverse fields of wellness and healthy longevity, something that rarely comes up is the use of biomarkers, either to suggest a practice direction or to monitor results of interventions. As a Medical Biochemist, and past director of a department of Pathology and Laboratory Medicine, for me, precise and accurate outcome measurement is a fundamental tenet of good practice. In today's conversation we are going to discuss how biomarkers can be used to optimize health and performance and how we can  use food as medicine.My guest today is Ari Tulla, a San Francisco-based entrepreneur,  angel investor and advisor, with a portfolio of 40 startups, including Virta Health, Good Eggs, and Ōura. Ari was the CEO of Quest Analytics, the market leader in doctor data and network management, and co-founder and CEO of BetterDoctor, a doctor search engine. He is the co-founder & CEO of Elo, the smart nutrition service, whose mission is to transform food from the leading cause of disease, to medicine.  When not working or co-parenting his two young children with his wife, Ari spends his time on the steep cliffs, powdery slopes, and big cold waves that only Northern California can offer. I asked Ari whether tackling the steep cliffs and big cold waves was done to trigger hormesis, the principle that short, intermittent bursts of stressors like extreme cold trigger a cascade of cellular reactions that enhance overall health, slow aging, to make one more resilient to future stress. Or does he just surf and ski for the fun of it?  He said both. We discussed how biomarkers as part of a comprehensive battery of test can be useful in directing the use of food and medicine.Learn more about Ari  at the links in the show notes.https://www.linkedin.com/in/aritulla/ https://www.linkedin.com/company/elo-health/ Contact Dr. Gillian Lockitch: To discover how to Reset Your Aging Blueprint and create your own roadmap to living younger as you grow older, you can schedule a free Discovery Call with me.Order your copy of Growing Older Living Younger: The Science of Aging Gracefully and The Art of Retiring Comfortably here  and join our private Growing Older Living Younger Community, to meet people, who like you, are discovering and sharing ways to age in great health.And remember to subscribe, rate and review the show.

In this exclusive interview, Hannes Hagström joins Jörn Schattenberg, Louise Campbell and Roger Green to explore papers emerging from Scandinavia which offer fascinating insights to the field at large.Hannes opens the conversation with his idea that 2022 was an encouraging year for research, specifically in that the mechanisms of drugs in development “feel more realistic.” When asked what he means by realistic, Hannes explains his interpretation of NAFLD to be a public health problem by which the metabolic system is overloaded with nutrients. He suggests a general pathway would aim to reduce this burden, citing examples like GLP-1s and possibilities surrounding an imminent announcement on resmetirom. From here Hannes describes developing a population-based cohort of liver disease patients using relatively accurate registers in Sweden. He highlights that this system enables studies to navigate issues around selection bias and capture the whole of a population with any diagnosed liver disease dating back to the sixties - roughly 350,000 unique patients in Sweden. The data available in this cohort can be linked back to the general population and used to examine several important research considerations. Long-term outcomes of chronic liver diseases, risk factors for disease progression, impact of dispensed drugs, disease panorama and time trends are among examples.Segueing to several studies utilizing this cohort, Hannes first introduces a paper which examines cardiovascular disease (CVD) risk and life expectancy in patients with NAFLD compared with the general population. While NAFLD was associated with a higher risk of nonfatal CVD, it notably did not affect post-CVD mortality risk. Another conclusion: patients diagnosed with NAFLD have a lower life expectancy than the general population. Strikingly, this loss in life expectancy was accentuated depending on the age of patient at time of diagnosis. The younger in age one has a diagnosis of NAFLD, the more one can expect to have a drop in life expectancy. Hannes suggests this may summon an urgency in screening younger populations. A caveat of this cohort is noted to be the reality of true incidence rates could be higher than what has been captured in diagnosis in specialty care. At this point, Jörn and Louise ask a series of thought-provoking questions which spur Hannnes to describe additional compelling facets of working with this rich data set. Studies can link research cohorts examining biopsies of patients with NAFLD to these registers, allowing for long-term follow-up. Hannes also mentions collaboration with the Swedish Diabetes Register which captures at least 90% of patients with type 2 diabetes. Such granularity enables investigation into the influence of comorbidities on the risk of liver disease. Roger notes a theme of recent guidelines is to assume that diabetic patients have NAFLD, therefore the recommendation is to immediately search for NASH in the evidence of fibrosis. As these databases are pooled, NAFLD can be examined through a diabetes lens or vice versa. The group goes on to briefly discuss elements of screening, guidelines and the influence of NITs on interpreting prevalence. Hannes bridges this discussion to a just-accepted paper whereby his team looked at developing FIB-4 in a more meaningful way through stratifying subgroups within the overarching risk categories. Simply, the three parameters used are age, presence of diabetes and a gamma-glutamyl transferase test. The latter is noted to be useful in linking cardiac outcomes and an imperfect marker for alcohol use. As the session winds down, the panelists explore speculative questions around genetics and the microbiome, and any foresight into how these factors could be filtered through the aforementioned registers and databases. In closing, Hannes provides a glimpse at what awaits for his research in 2023. Surf on to find out. 

Dr Omid Hamid from the Angeles Clinic and Research Institute in Los Angeles, California, discusses novel immunotherapies and combination treatments for patients with metastatic melanoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelStrategiesMelanoma22).

Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted' therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism? Moderated by: Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy Panelists: Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI) Learn more about the IO360° Summit at www.io360summit.com

Our guest to the podcast today is Oliver Patrick, a Physiologist and leading expert in lifestyle management. He speaks widely on the application of wellbeing strategies and consults to businesses and individuals around the world. Oliver was Head of Physiology at Nuffield Hospitals where he led the largest team of applied physiologists, wellbeing advisors and nutritionists in the UK. In 2009, he co-founded Viavi on London's Harley St, to deliver the world's most advanced health assessment and health evaluation service. Alongside advanced health assessments, he co-founded the first Lifestyle medicine gym in Oxford. Oliver now runs a corporate wellbeing consultancy service and has founded an industry specific education platform to drive practical coaching skills in the broader undervalued areas of lifestyle particularly stress, sleep, toxicity and mindset. Today, we discuss the 4 key things to change physically to reap the best biological benefits, the multifactorial approach to wellbeing – in terms of the physical, mental and emotional aspects and the opportunities the fitness industry needs to grasp quickly in order to better impact the lifestyles of its customers. To learn more about Oliver Patrick, click here! https://www.oliverpatrick.com/

Welcome to day 10 of 12 Days of Biohacking Gifts! Each day I interview a different health and wellness brand, host a giveaway for their products on my Instagram account, and share valuable information with you on how they're shaping the biohacking world.  I interview Michelle Darian from InsideTracker. We talk about what InsideTracker is, why they test for specific biomarkers and not others, and why you should get your blood tested regularly.  InsideTracker uses the power of Big Data to make user data more meaningful and actionable. Their engine generates a vast array of potential nutrition, supplement, fitness and lifestyle interventions customized to each individual user of the InsideTracker platform. Join the giveaway by going to my Instagram account - @biohackingbrittany.     We talk about:  02:00 - What InsideTracker is 03:40 - What to do after getting tested with InsideTracker 06:00 - Why InsideTracker tests for specific biomarkers and not others 08:30 - Michelles's test results from InsideTracker 10:30 - Using a food-first approach 12:30 - Biomarkers and your biological age 14:45 - Customer feedback from the Inner Age results from InsideTracker 16:00 - HBA1C and your Inner Age 20:00 - Why it's important to test your blood biomarkers     Resources:  Visit InsideTracker and enter code BIOHACKINGBRITTANY to get a discount on their plans.     Let's connect: Instagram Facebook TikTok Subscribe to my newsletter Shop my favorite health products Listen on Spotify, Apple Podcasts, Google Podcasts

Multiple Sclerosis News Today's multimedia associate, Price Wooldridge, reports on how individuals with PPMS have significantly higher concentrations of specific inflammation biomarkers in their spinal fluid than healthy people. 

He also reads MS News Notes: Climate Change, MS Progression, Brain Shrinkage” by Ed Tobias, from his column “The MS Wire.” =================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

To kick off our series on August papers, we will talk all about different ways that synaptic transmission may be affected in Alzheimer's disease, with 6 research papers that use either cell models, animal models, or human patients. Stay tuned!  Sections in this episode:  Cortical signaling in rodent models (3:15)  New AD models (8:32)  Biomarkers of neural dysfunction in humans (9:24)  -------------------------------------------------------------- To find the numbered bibliography with all the papers covered in this episode, click here, or use the link below:https://drive.google.com/file/d/1iLzCzMAIoIYq7fW_zJ2Lr_8CoKnr5fR5/view?usp=share_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: www.amindr.com. --------------------------------------------------------------Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted, hosted, and edited by Ellen Koch, and reviewed by Anusha Kamesh. The bibliography and wordcloud were created by Lara Onbasi (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For July 2022, the sorters were Sarah Louadi, Eden Dubchak, Ben Cornish, Christy Yu, Dana Clausen, Kevin Nishimura, Ellen Koch, and Elyn Rowe. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, and Lara Onbasi for keeping everything running smoothly.Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!"  

Dr Eric Sherman from Memorial Sloan Kettering Cancer Center in New York City discusses recent therapeutic advances in thyroid cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayThyroid22).

Dr Jeffrey Zonder from Karmanos Cancer Institute in Detroit, Michigan discusses the biology, presentation and current management of AL amyloidosis and emerging data with novel therapies. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALAmyloidosis22).

Drs. Tina McKay and Zhongcong Xie discuss delirium biomarkers with Dr. Adam Striker. Learn about the latest research, the practical implications for patient safety, the connection between delirium biomarkers and Alzheimer's disease, and more. Recorded November 2022.  This podcast episode was developed in collaboration with the Committee on Geriatric Anesthesia and funded by ASA's Industry Supporters. Thank you to our Industry supporters for their year-round support of ASA: Baudax Bio, Edwards Lifesciences, Fresenius Kabi, GE Healthcare, Heron Therapeutics, Masimo, Medtronic, and Merck. 

A new research paper was published in Oncotarget's Volume 13 on November 22, 2022, entitled, “Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis.” Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. In the current study, researchers Yuji Morine, Tohru Utsunomiya, Hisami Yamanaka-Okumura, Yu Saito, Shinichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Shohei Kinoshita, Akiyoshi Hirayama, Yasuhito Tanaka, and Mitsuo Shimada from Tokushima University Graduate School, Keio University and Kumamoto University used metabolomics to discover potential biomarkers of hepatocellular carcinoma (HCC). The team investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis–time-of-flight mass spectrometry. They also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. “In the present study, we sought to discover reliable metabolomic biomarkers for HCC diagnosis by elucidating metabolic alterations in primary HCC tumor tissue compared with non-tumor tissue, and additionally by investigating the serum metabolomic profiles before and after curative hepatectomy.” Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (EAA) (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. The results of this study revealed striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identified the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC. “In this study, the major findings were (i) the metabolomic profile of HCC tumors differs not only compared with matched non-tumor liver tissue but also with CRLM tissue, (ii) the serum metabolome of HCC patients is altered by hepatectomy, and (iii) the three EAAs leucine, valine, and tryptophan are candidate metabolomic biomarkers for hepatocarcinogenesis. Notably, however, we found that the metabolic profiles of HCC tumor tissues of differing etiologies (HBV/HCV infection) could not be distinguished, nor could the profiles of non-tumor liver tissue from any of the patient subgroups.” DOI: https://doi.org/10.18632/oncotarget.28306 Correspondence to: Yuji Morine - ymorine@tokushima-u.ac.jp Keywords: metabolomics, essential amino acid, hepatocellular carcinoma, diagnostic biomarker To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter - https://twitter.com/Oncotarget Facebook - https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram - https://www.instagram.com/oncotargetjrnl/ LinkedIn - https://www.linkedin.com/company/oncotarget/ Pinterest - https://www.pinterest.com/oncotarget/ LabTube - https://www.labtube.tv/channel/MTY5OA SoundCloud - https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics. Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders Episode Breakdown: 1:20 – An overview of the state of virtual reality in medicine 2:20 – The Cleveland Clinic Virtual Reality Shopping platform 6:45 – The importance of mimicking the details of reality 8:05 – Misconceptions and surprises with VR for Parkinson disease 11:45 – Neurology News Minute 15:05 – How VR can be used in prodromal Parkinson disease  19:00 – Biomarkers for Parkinson disease 21:15 – Using VR as a targeted therapy 23:20 – The opportunity in medicine with VR systems This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation Duchenne Gene Therapy SRP-9001 Wins Priority Review Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Discover 10 scientifically proven ways to boost your metabolism to lose weight fast. This episode reveals the best diet for weight loss, how coffee and caffeine help assist in burning more calories, the best fats to eat for fat loss, and more! / / E P I S O D E   S P ON S O R S  Dr Phillips CBD Oil & Keto Fruit Chews. Visit www.drphillipscbd.com Good Idea Functional Sparkling Water Drinks. Visit http://www.goodidea.us and use the coupon code KETOKAMP at checkout.  Text me the words "Podcast" +1 (786) 364-5002 to be added to my contacts list.  00:55​ The first way is with broccoli sprouts. Broccoli sprouts has many benefits, and one of them is with weight loss. Study: sci-hub.do/10.1016/j.clnu.2018.03.006 After 10 weeks of daily broccoli sprout consumption, weight and BMI were not altered, but body fat mass significantly decreased Limitations: no randomized control group so causality can't be inferred, but there were also significant reductions in inflammatory markers (IL-6, CRP) [obesity characterized by chronic low-grade inflammation] 500mg daily Supplement: https://amzn.to/3uOTbFe​ 02:20​ Turmeric helps you lose weight! sci-hub.do/10.1002/biof.1074 Obesity contributes to chronic low-grade inflammation. Curcumin may suppress inflammation by directly interacting with white adipose tissue. Curcumin may also increase antioxidant activity and decrease adipocyte differentiation. https://www.ncbi.nlm.nih.gov/pmc/arti...​ Curcumin Attenuates Adipogenesis by Inducing Preadipocyte Apoptosis and Inhibiting Adipocyte Differentiation https://pubmed.ncbi.nlm.nih.gov/31799...​ The effects of curcumin supplementation on body mass index, body weight, and waist circumference 70 - 2,400mg daily Supplement: https://amzn.to/30juNh3​ 03:41​ Coffee/tea (caffeine) helps you lose weight fast. sci-hub.do/10.1056/NEJMra1816604 Caffeine may reduce appetite and increase basal metabolic rate. Caffeine intake may modestly reduce body fat Caffeine intake throughout the day led to a 5% increase in 24-hour energy expenditure sci-hub.do/10.1093/ajcn/nqz306 Participants drinking coffee versus placebo experienced greater loss of fat mass Recommended dose is around 100mg per day ☕Coffee: http://www.ketokampcoffee.com​ Use "ketokamp" for 10% off 04:51​ Spicy foods have a component in it called capsaicin which can speed up your metabolism. https://www.ncbi.nlm.nih.gov/pmc/arti...​ Consumption of foods containing capsaicin associated with lower prevalence of obesity. Capsaicin may help sustain fat oxidation, increase resting energy expenditure,. Chilli pepper may increase energy expenditure by triggering BAT (brown adipose tissue) activity [similar to cold thermogenesis] Recommended dose 1,500mg per day Supplement: https://amzn.to/3r9Tx6V​ 05:55​ Astaxanthin has many health benefits including weight loss. sci-hub.do/10.1002/ptr.3494 The strong antioxidant properties of astaxanthin may play a role in reducing oxidative-stress (being overweight or obese may increase oxidative stress). Biomarkers of oxidative stress decreased after supplementation with astaxanthin. Dosage: 8mg per day Supplement: https://amzn.to/305c7kL​ 06:59​ The best fats for weight loss are walnuts, hemp seeds, sunflower seeds, avocado oil, eggs. https://www.ncbi.nlm.nih.gov/pmc/arti...​ High omega-3 fatty acid intake contributes to homeostasis and weight loss versus high omega-6 fatty acid intake which increases leptin & insulin resistance. 08:46​ The best diet for weight loss is the keto diet. https://www.mdpi.com/2075-4663/8/10/1...​ sci-hub.do/10.1080/07315724.2020.1725686 KETO PLAYLIST: https://bit.ly/37jbybL​ 09:57​ Exercise in the morning helps with weight loss. sci-hub.do/10.1139/apnm-2019-0917 https://www.nature.com/articles/s4136...​ GC3 FITNESS: https://bit.ly/3e3JMno​ 10:51​ Fasting for serious weight loss. sci-hub.do/10.1007/s11154-019-09524-w sci-hub.do/10.1017/S0029665119000636 https://pubmed.ncbi.nlm.nih.gov/32003...​ 12:53​ Fasted exercise https://www.ncbi.nlm.nih.gov/pmc/arti...​ sci-hub.do/10.3390/nu12082349 https://pubmed.ncbi.nlm.nih.gov/30334...​ https://pubmed.ncbi.nlm.nih.gov/29315...​ *Links Are Affiliates* // F O L L O W ▸ instagram | @thebenazadi | http://bit.ly/2B1NXKW​ ▸ facebook | /thebenazadi | http://bit.ly/2BVvvW6​ ▸ linkedin | http://bit.ly/2PNRh40​ ▸ email | support@ketokamp.com

Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses therapeutic advances in the management of patients with myelofibrosis. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsMF22).

This episode, Dr. Douglas Taren speaks with Mateus de Lima Macena and Dr. Nassib Bezerra Bueno from Universidade Federal de Alagoas, Maceió, Alagoas, Brazil. Their article assesses effects of dietary polyphenols, from food sources or supplements, on the anthropometric, glycemic, renal, inflammatory, and oxidative stress markers in adults with diabetic nephropathy (DN). Join us for this conversation with this month's featured authors.

Special guests John Bucksath, CEO of KCAS in Olathe, KS and Marc Essodaigui, General Manager of Active Biomarkers in Lyon, France, join Dom and John this week as they introduce our listeners to Active Biomarkers – the most recent acquisition of KCAS in the European space. The gentlemen discuss a brief history of Active Biomarkers, the path to their acquisition by KCAS, and what it now means – for both the organizations as well as their customers and the industry – now that these two CROs have come together to couple their skillsets."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA and Milan, Italy, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

In this episode, Austin J (hallucinodream) follows up to last week's episode which was on the difference between genetics and lifestyle, or habits! He also answers any questions that may have come in during the week leading up to this episode. *Episode disclaimer: Please note that nobody in this episode is a doctor, a registered dietician or any medical professional. The information in this episode is purely research based or anecdotal based. This information is not to be used to diagnose, treat, or cure any medical condition. The episode is for educational purposes. This episode is hosted by Austin J (@hallucinodream)! If you have any questions on anything you heard in this episode, feel free to ask by sending us a message on any of our social media platforms and we will be happy to answer them in follow up episodes! Also, be sure to put some tips to use, and share your stories with us on social media! Ready to get the same blood panel that Austin J (hallucinodream) gets? Check out Inside Tracker's plan and pick the one that suits your needs! Use the code below for a discount that can be used across the whole online store! -Inside Tracker: https://www.insidetracker.com/ -25% off full store with code: AUSTINPRO25 // Enjoying the Podcast? Help support us by becoming a Patreon today! // https://www.patreon.com/1PUNCH // Each tier comes with their own benefits! // Be sure to check them out and choose the best suited for you! // And as always, thank you in advance for the love and support! ----- Podcast Posting Schedule: -1st and 3rd Thursday of every month: Regular Episode -2nd and 4th Thursday of every month: Follow up and Q&A to previous week's podcast. -5th Thursday of every month: Fun Episode with more Q&A from current or past episodes! Check us out on our website and social media: -Website: https://www.1PUNCH.net -Instagram: https://www.instagram.com/1PUNCHNation -TikTok: https://www.tiktok.com/@1PUNCHNation -Twitter: https://www.twitter.com/1PUNCH -Twitch: https://www.twitch.tv/1PUNCH -YouTube: https://www.youtube.com/1PUNCH Check out those who took part in this podcast: Host: Austin J / hallucinodream -Instagram: https://www.instagram.com/hallucinodream -TikTok: https://www.tiktok.com/@hallucinodream -Twitter: https://www.twitter.com/hallucinodream -Twitch: https://www.twitch.tv/hallucinodream -YouTube: https://www.youtube.com/hallucinodream Thank you for the support, and don't forget to hit that subscribe button! #1PUNCH #Health #Wellness #Gaming #Podcast #Nutrition #Carbohydrates #Carbs

Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC22).

Tessa Peters and Dr Leticia Pías-Peleteiro join the podcast to discuss GLUT1 deficiency syndrome and recent insights around the potential for new biomarkers. Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficit Tessa M. A. Peters, et al https://doi.org/10.1002/jimd.12554

We know that hydrogen is the most abundant element in the universe, while oxygen is the most common in the Earth's crust. We know that together, they make up water, one of the most crucial resources for our survival. But did you know that through electrolysis of H2O, a special mixture of gas is produced that has amazing therapeutic benefits?In this episode, we have George Wiseman. Beyond being an enjoyable and insightful guest, George is a purveyor of science, inventor, and the creator of AquaCure–a device that generates Hydrogen-rich water and the electronically-expanded water called Brown's Gas. Let's take a deeper look into the science and effects of Brown's Gas, its fascinating overlap with decades of research on the therapeutic effects of hydrogen, and more! I'm excited to have you dive in!HIGHLIGHTS[00:00] George Wiseman[04:05] Brown's Gas for Health Purposes[15:53] Sharing Brown's Gas with Others[23:33] What is Brown's Gas, and How Does it Help?[30:58] What Happened When George Used Brown's Gas[35:38] Hydrogen Balance, Nutrition, and Improving Public Health[42:59] Brown's Gas and Natural Healing[48:29] The Effect of Brown's Gas in a Person-to-Person Context[54:27] Biomarkers and Scientific Studies of Hydrogen for Health[58:51] Applications of Brown's Gas[1:08:09] On Stacking Brown's Gas with Other Alternative Wellness Treatments[1:20:02] On Building a Bridge Between Allopathic and Alternative Medicine[1:25:37] Promo for the Aquacure Device UPGRADE YOUR WELLNESSGet a 20% discount on an AquaCure MachineWebsite:  eagle-research.lifeCode: beautifullybrokenClaim your free toxicity consult through this LINKAMD Ion Cleanse: https://calendly.com/ioncleanse/detoxSilver Biotics 30% Off SitewideCode: BEAUTIFULLYBROKENSphere: sphere.guideCode: BEAUTIFULLY25DIY Home Cold Exposure: https://www.penguinchillers.com/product/beautifullybroken/ Cellcore – https://www.beautifullybroken.world/affiliate-products My favorite BindersRe-Origin Limbic Training: https://re-origin.com/?ref=18Code: beautifullybroken LightPath LED   https://lightpathled.com/?afmc=BEAUTIFULLYBROKENDiscount Code – beautifullybroken BioStrap: https://biostrap.com/order-evo?ref=freddiekimmelp My Favorite Recovery TrackerDiscount: BEAUTIFULLYBROKEN Fully Vital Hair Restoration: https://fullyvital.com/BEAUTIFULLYBROKEN15 My Favorite Sauna: Therasage https://bit.ly/39mTxwYCode: BEAUTIFULLYBROKEN CONNECT WITH FREDDIE Check out my website and store:www.beautifullybroken.worldJoin my membership program –https://www.buymeacoffee.com/freddiesetgoInstagram – https://www.instagram.com/freddiesetgo/

Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma. CME information and select publications [here] (http://www.researchtopractice.com/OncologyTodayHCC22)

Three Thanksgiving Health Tips from  Dr. Michael Koren and Kevin Geddings on the MedEvidence Monday Minute.You will learn:

In this episode, Austin J (hallucinodream) goes over an often overlooked topic of importance. Understanding the difference of the "its in my genes" mentality versus lifestyle, habits, and environmental impacts, can help move a person forward with their wellness journey. Further, it can help to create new healthy habits not only for themselves, but even for their family as well! *Episode disclaimer: Please note that nobody in this episode is a doctor, a registered dietician or any medical professional. The information in this episode is purely research based or anecdotal based. This information is not to be used to diagnose, treat, or cure any medical condition. The episode is for educational purposes. This episode is hosted by Austin J (@hallucinodream)! If you have any questions on anything you heard in this episode, feel free to ask by sending us a message on any of our social media platforms and we will be happy to answer them in follow up episodes! Also, be sure to put some tips to use, and share your stories with us on social media! Ready to get the same blood panel that Austin J (hallucinodream) gets? Check out Inside Tracker's plan and pick the one that suits your needs! Use the code below for a discount that can be used across the whole online store! -Inside Tracker: https://www.insidetracker.com/ -25% off full store with code: AUSTINPRO25 // Enjoying the Podcast? Help support us by becoming a Patreon today! // https://www.patreon.com/1PUNCH // Each tier comes with their own benefits! // Be sure to check them out and choose the best suited for you! // And as always, thank you in advance for the love and support! ----- Podcast Posting Schedule: -1st and 3rd Thursday of every month: Regular Episode -2nd and 4th Thursday of every month: Follow up and Q&A to previous week's podcast. -5th Thursday of every month: Fun Episode with more Q&A from current or past episodes! Check us out on our website and social media: -Website: https://www.1PUNCH.net -Instagram: https://www.instagram.com/1PUNCHNation -TikTok: https://www.tiktok.com/@1PUNCHNation -Twitter: https://www.twitter.com/1PUNCH -Twitch: https://www.twitch.tv/1PUNCH -YouTube: https://www.youtube.com/1PUNCH Check out those who took part in this podcast: Host: Austin J / hallucinodream -Instagram: https://www.instagram.com/hallucinodream -TikTok: https://www.tiktok.com/@hallucinodream -Twitter: https://www.twitter.com/hallucinodream -Twitch: https://www.twitch.tv/hallucinodream -YouTube: https://www.youtube.com/hallucinodream Thank you for the support, and don't forget to hit that subscribe button! #1PUNCH #Health #Wellness #Gaming #Podcast #Nutrition #Carbohydrates #Carbs

People who love wearables often complain that their biomarker data that gets collected in one app stays in that app, and the apps don't talk to each other. Kyriakos Eleftheriou, CEO and Co-Founder of Terra, shares with Ben Grynol how he's building Terra to standardize biomarker data and translate it into one language. By doing this, Terra could enable users to connect their data from wearables to non-health-tech companies like Spotify or Netflix, providing real-time recommendations that would help give a certain mood based on a person's physical state; for example, an uplifting movie suggestion during a stressful time. Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health. Look for multiple new shows per week on A Whole New Level, where we have in-depth conversations about metabolic health and how the Levels startup team builds a wellness movement from the ground up in the health and wellness tech industry.

Dr. Howard Fillit, the Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, focuses the nonprofit on supporting scientists around the globe who are investigating novel drugs to prevent, treat and cure Alzheimer's disease. He explains to hosts Mark Masselli and Margaret Flinter how those investments are paying dividends in terms of diagnostic tools and treatments and why the upcoming holidays are a perfect time to assess if a loved one is showing signs of dementia. The post Alzheimer's Foundation Head Discusses Breakthroughs: Can Biomarkers & Vaccines Offer Hope? appeared first on Healthy Communities Online.

Dr Eytan Stein from Memorial Sloan Kettering Cancer Center in New York City discusses novel agents and strategies in the treatment of acute myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsAML22).

Emi Gal shares the lessons he's learned building Ezra, why he tracks 150 different biomarkers, what he's learned doing a Yearly Challenge for the last 14 years, and why he's focused on achieving peak health by 40, and more. As well as the origin story behind his extreme discipline and his advice for others that want to become more disciplined. “To make progress in anything, but especially your health, you just need to nudge behavior a little bit every day. I find that tracking 150 different biomarkers does that quite well for me.” — Emi Gal EPISODE GUIDE (LINKS, QUOTES, NOTES, AND BOOKS MENTIONED) https://www.danielscrivner.com/notes/emi-gal-ezra-20-minute-playbook   FULL TEXT TRANSCRIPT https://www.danielscrivner.com/notes/emi-gal-ezra-20-minute-playbook-transcript    CHAPTERS (00:00:00) - Introduction (00:01:27) - Why and How Emi Gal Tracks 150 Different Biomarkers (00:05:50) - How Emi Gal is Reaching Peak Health by The Age of 40 (00:08:54) - The Relationship Between Bone Density and Exercise (00:10:27) - Why Emi Gal Has Done a Yearly Challenge Every Year Since 2008 (00:18:16) - Lessons Learned Studying and Becoming Antifragile (00:22:23) - Lessons Learned from Studying with a World Memory Champion (00:26:56) - Lessons Learned from Interviewing Elderly Americans (00:31:31) - Why People Would Be Surprised at Emi Gal's Discipline (00:34:06) - How to Become More Disciplined (00:39:05) - Emi Gal's Favorite Books: Antifragile and The Patient Will See You Now (00:42:57) - Emi's Advice for His Younger Self: Embrace Optionality Early On ABOUT THE GUEST Emi Gal started his first company, Brainient, when he was just 19. He spent 10 years building Brainient into one of the leading ad-tech companies in Europe before it was acquired by Teads—one of the largest advertising platforms in Europe, with 1.8-billion impressions per month. After working with Hospices for Hope, a non-profit in Romania that builds and operates hospices for terminally ill cancer patients, Emi realized that one of the biggest problems with cancer is the lack of a fast, accurate, affordable way to screen for cancer everywhere in the body. He founded Ezra in 2018 to solve this problem using Magnetic Resonance Imaging (MRI) and Artificial Intelligence. To date, he's reduced the cost of getting a full-body cancer screening by 80% and reduced the time required to get screened by 66%.

Dr Amy DeZern from The Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, discusses recent therapeutic advances in higher-risk myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHigherRiskMDS22).

Listen as we decode how Emi Gal tracks more than 150 different biomarkers, what he's learned doing an Annual Challenge for the last 14 years, why he's focused on achieving peak health by 40, how to become more disciplined, and more. Emi Gal is the Founder & CEO of Ezra, which is bringing fast and affordable cancer screening to everyone.

Dr Rachna Shroff from the University of Arizona Cancer Center in Tucson, Arizona, discusses data and the practical implications from key gastrointestinal cancer presentations made at recent major oncology conferences. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGI22).

Lucy D'Agostino McGowan and Ellie Murray chat about counterfactuals! Follow along on Twitter: The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats